Multidrug-Resistant Bacteria in Immunocompromised Patients
Pharmaceuticals · 30.08.2024 · 17 (9) · 1151
DOI: 10.3390/ph17091151 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 30.08.2024. Verfasst von Alexandru Duhaniuc und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Preventive Medicine and Interdisciplinarity-Microbiology, University of Medicine and Pharmacy "Grigore T. Popa", 700115 Iasi, Romania. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: "Grigore T. Popa" University of Medicine and Pharmacy, University of Medicine and Pharmacy “Grigore T. Popa”.
Abstract (Originalsprache)
The increasing incidence of antibiotic resistance in bacteria is a major problem in terms of therapeutic options, especially in immunocompromised patients, such as patients from intensive care units (ICUs), HIV-positive patients, patients with malignancies or transplant patients. Commensal bacteria, especially anaerobes, serve to maintain microbial stability by preventing overpopulation with pathogenic bacteria. In immunocompromised patients, microbiota imbalance caused by antibiotic therapy and decreased host immunity favors intestinal overpopulation with pathogenic species, leading to increased bacterial translocation and susceptibility to systemic infections. Infections with multidrug-resistant (MDR) bacteria pose major challenges to the establishment of appropriate treatment and lead to increased mortality. Asymptomatic colonization with MDR bacteria usually precedes infection and tends to persist for long periods of time, and in immunocompromised patients, colonization with MDR bacteria is a risk factor for systemic infections. This review aims to assess the relation between colonization and infection with MDR bacteria in immunocompromised patients such as ICU patients, HIV-positive patients and cancer patients and to identify the prevalence and patterns of MDR bacterial colonization and infection in this category of patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Preventive Medicine and Interdisciplinarity-Microbiology, University of Medicine and Pharmacy "Grigore T. Popa", 700115 Iasi, Romania.
- National Institute of Public Health-Regional Center of Public Health, 700465 Iasi, Romania.
- "Dr. C.I. Parhon" Clinical Hospital, 700503 Iasi, Romania.
- Department of Internal Medicine II-Infectious Diseases, University of Medicine and Pharmacy "Grigore T. Popa", 700115 Iasi, Romania.
- Clinical Hospital of Infectious Diseases "Sf. Parascheva", 700116 Iasi, Romania.
ORCID-Profile: Alexandru Duhaniuc, Eduard-Vasile Nastase, Felicia Trofin, Luminița-Smaranda Iancu, Olivia-Simona Dorneanu
Förderung
- "Grigore T. Popa" University of Medicine and Pharmacy
- University of Medicine and Pharmacy “Grigore T. Popa”
Zitieren
APA
Duhaniuc, A., Păduraru, D., Nastase, E. V., Trofin, F., Iancu, L. S., Sima, C. M., & Dorneanu, O. S. (2024). Multidrug-Resistant Bacteria in Immunocompromised Patients. Pharmaceuticals, 17(9), 1151. https://doi.org/10.3390/ph17091151
Vancouver
Duhaniuc A, Păduraru D, Nastase EV, Trofin F, Iancu LS, Sima CM, et al. Multidrug-Resistant Bacteria in Immunocompromised Patients. Pharmaceuticals. 2024;17(9):1151. doi:10.3390/ph17091151
BibTeX
@article{Duhaniuc2024,
author = {Duhaniuc, Alexandru and Păduraru, Diana and Nastase, Eduard-Vasile and Trofin, Felicia and Iancu, Luminița-Smaranda and Sima, Cristina-Mihaela and Dorneanu, Olivia-Simona},
title = {Multidrug-Resistant Bacteria in Immunocompromised Patients},
journal = {Pharmaceuticals},
year = {2024},
volume = {17},
number = {9},
pages = {1151},
doi = {10.3390/ph17091151}
}
EUVIMED